Series C Preferred was acquired by Vivos Therapeutics, Inc., according to the Form 8-K Vivos Therapeutics, Inc. filed with the SEC. It is the only completed acquisition Vivos Therapeutics, Inc. reported under Item 2.01 in the last twelve months (Form 8-K, October 19, 2026).
1 companies announced an acquisition this week.
Companies in an acquisition this week, and the deal. Before you unlock: the company, the deal and what is inside. After: every way we found to reach the company, and anyone a source names. A team joining the buyer is labelled only when the filing itself says so.
| Bowman Consulting Group Ltd. | agreed to be acquired by Prive Parent, Inc. |
Competing with, selling to or investing in Vivos Therapeutics, Inc. after this deal? See the free Snapshot first.
Free to see. No signup.
Vivos Therapeutics, Inc. completed its acquisition of Series C Preferred, according to the Form 8-K Vivos Therapeutics, Inc. filed with the SEC on 2026-10-19. The filing's Item 2.01 states no aggregate dollar price.
| Acquirer | Vivos Therapeutics, Inc. |
|---|---|
| Acquired | Series C Preferred |
| Reported by | Vivos Therapeutics, Inc. (VVOS), the buyer |
| Filing | Form 8-K, filed 2026-10-19 |
Want the whole picture on Vivos Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Vivos Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vivos Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
SOD represented that it acquired the Series C Preferred for its own account for investment and not with a view to distribution.
More from the filing
On the Closing Date, the Company issued 12,000 shares of Series C Preferred to SOD in exchange for the SOD Shares and the Test Interest.
Each share of Series C Preferred is convertible, at the option of the holder, into the number of shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), determined by dividing the $1,000 stated value by the conversion price of $0.15 per share, subject to proportional adjustment for stock splits, reverse stock splits, combinations, stock dividends and similar events and to the Exchange Cap and the Beneficial Ownership Limitation described in Item 5.03 below.
At the $0.15 conversion price, the Series C Preferred is convertible into up to 80,000,000 shares of Common Stock in the aggregate; until stockholder approval is obtained, no more than 6,718,517 shares of Common Stock (based on 19.99% of the 33,609,393 shares of Common Stock outstanding prior to the signing of the Agreement) may be issued upon conversion.
Quoted from Vivos Therapeutics, Inc.'s Form 8-K.
This is the only completed acquisition Vivos Therapeutics, Inc. reported under Item 2.01 in the last twelve months.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Vivos Therapeutics, Inc.Look up Vivos Therapeutics, Inc. first. Finding the company and seeing how much is on record uses no credits.
Look up Vivos Therapeutics, Inc.Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.